Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Tenofovir disoproxil fumarate (TDF), the first nucleotidic inhibitor of HIV reverse transcription, became available in 2001. It has been extensively used worldwide and is now the most prescribed antiretroviral (ARV) drug. Its high antiviral activity and favorable metabolic profile are responsible for its success. Furthermore, TDF has been associated with other ARVs to form new combined antiretroviral treatments in only one tablet once-a-day, which increases treatment adherence. Fears of potential nephrotoxicity that tenofovir would have in common with two other drugs from the same family (adefovir, used to treat hepatitis B, and cidofovir, used to treat cytomegalovirus infections) were alleviated by the early clinical trials. Yet, in 2001, the first case of TDF-induced acute nephrotoxicity was published. Numerous cases have been published since then, and it is now established that TDF presents a tubular toxicity risk. Some facilitating factors have been identified, such as co-prescription of didanosine or boosted protease inhibitor, preexisting CKD, low body weight, and associated diabetes mellitus. Conversely, whether TDF is nephrotoxic in the long term is a highly debated question. Some studies suggest a decreased GFR when TDF is prescribed for a long period, while others indicate that TDF is safe for the kidneys even after many years of use. Here we review the differences in patient characteristics, study designs, and measured outcomes that can possibly explain these conflicting findings. We conclude with rational recommendation for appropriate TDF prescription.
Nephrology Department, Groupe Hospitalo-Universitaire Pitié-Salpêtrière and Université Pierre et Marie Curie, Paris, France.
Jérôme
J
Tourret
Gilbert
G
Deray
Corinne
C
Isnard-Bagnis
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D007668:Kidney / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D010757:Phosphorous Acids / Q000009:adverse effects*; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology / Q000503:physiopathology; D012307:Risk Factors
C574165:9-(2-((bis(pivaloyloxymethoxy)phosphinoyl)methoxy)propyl)adenine; D018501:Antirheumatic Agents; D010757:Phosphorous Acids; D000225:Adenine